Values as of: 2025-04-17
ETF | Large Blend | NYSE Arca
Last Closing
USD 26.051Change
+0.04 (+0.16)%Market Cap
USD 0.11BVolume
300.00Analyst Target
N/A
N/A
Verdict
The investment seeks high current income with the potential for long-term capital appreciation, while also seeking to protect principal during unfavorable market conditions. Under normal market conditions, the fund will invest at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in income-producing debt and equity securities of foreign and domestic issuers, including the securities of foreign and domestic corporate and government entities.
Company Website : www.wbishares.com,
Currency: USD
Country : USA
Inception Date: 25/08/2014
Primary Benchmark: Russell 1000 Value TR USD
Primary Index: S&P 500 TR USD
Gross Expense Ratio: 0.99%
Management Expense Ratio: 1.05 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| SDMHF | Sartorius Stedim Biotech S.A | 3.58 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| VTI | Vanguard Total Stock Market In.. | 0.03 % |
N/A |
USD 423.10B |
| SPLG | SPDR® Portfolio S&P 500 ETF | 0.04 % |
N/A |
USD 56.21B |
| SCHX | Schwab U.S. Large-Cap ETF | 0.03 % |
N/A |
USD 48.13B |
| DYNF | BlackRock US Equity Factor Rot.. | 0.00 % |
N/A |
USD 14.67B |
| GSLC | Goldman Sachs ActiveBeta® U.S.. | 0.09 % |
N/A |
USD 12.23B |
| SPTM | SPDR® Portfolio S&P 1500 Comp.. | 0.04 % |
N/A |
USD 9.06B |
| SPLV | Invesco S&P 500® Low Volatili.. | 0.25 % |
N/A |
USD 7.46B |
| JQUA | JPMorgan U.S. Quality Factor E.. | 0.12 % |
N/A |
USD 5.39B |
| DIVO | Amplify CWP Enhanced Dividend .. | 0.94 % |
N/A |
USD 3.97B |
| SCHK | Schwab 1000 ETF | 0.05 % |
N/A |
USD 3.74B |
N/A
| Market Performance vs. Industry/Classification (Large Blend) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -8.29% | 62% | D | 39% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -8.29% | 62% | D | 37% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -9.22% | 10% | F | 26% | F | ||
| Dividend Return | 0.64% | 26% | F | 10% | F | ||
| Total Return | -8.58% | 10% | F | 23% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 1.67% | 3% | F | 35% | F | ||
| Dividend Return | 6.33% | 6% | D- | 13% | F | ||
| Total Return | 8.00% | 3% | F | 25% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 2.43% | 6% | D- | 45% | F | ||
| Dividend Return | 3.71% | 6% | D- | 41% | F | ||
| Total Return | 1.28% | 49% | F | 30% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 11.04% | 94% | A | 76% | C+ | ||
| Risk Adjusted Return | 33.59% | 7% | C- | 50% | F | ||
| Market Capitalization | 0.11B | N/A | N/A | N/A | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
